A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Efficacy and Safety of Namodenoson (CF102), an A(3) Adenosine Receptor Agonist (A(3)AR), As a Second-Line Treatment in Patients with Child-Pugh B (CPB) Advanced Hepatocellular Carcinoma (HCC).
JOURNAL OF CLINICAL ONCOLOGY（2019）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined